

# Respiratory Research Review™

Making Education Easy

Issue 159 – 2019

## In this issue:

- *Mortality, morbidity and hospitalisations due to influenza LRTIs*
- *Baloxavir marboxil for uncomplicated influenza*
- *Influenza vaccination and influenza-associated hospitalisations in children*
- *Invasive aspergillosis in ICU patients with severe influenza*
- *Rhinotherapy for treating the common cold*
- *Omadacycline for CAP*
- *β-lactam ±macrolide and mortality in CAP with low resistance risk*
- *Bacteriology and clinical outcomes of CCPIs*
- *Role of ultrasound-guided pleural biopsies in pleural infection*
- *Predicting tPA/DNase failure in complicated parapneumonic effusions/empyema*

### Abbreviations used in this issue

**CAP** = community-acquired pneumonia  
**CCPI** = culture-positive pleural infection  
**DNase** = deoxyribonuclease  
**LRTI** = lower respiratory tract infection  
**RCT** = randomised controlled trial  
**tPA** = tissue plasminogen activator

## Welcome to this issue of Respiratory Research Review with the focus on pneumonia and infection.

As we are producing this review, NZ is in the middle of a measles epidemic. The discussions are certainly stimulating to follow, whether it is an elected council member wearing 'antivaccination' clothing or, the debate, whether unvaccinated children should attend publicly funded schools or kindergartens, a path that Italy has taken. Like with influenza vaccination, we must be mindful of assisting people in accessing vaccinations, as a [study](#) from Liverpool highlights.

Last year was the centenary of the 1918 Influenza pandemic, which caused an estimated 90 million deaths. New research suggests that the majority of people died due to bacterial superinfection, probably via the breakdown of the epithelial barrier, impaired activation of the immune system, and immune paresis via increased IL-10. Wendy Barclay and Peter Openshaw published a great [review](#) in *Lancet Respir Med* and highlight the ever-present danger of a new, highly pathogenic avian influenza (H5N1), which has already crossed over into people exposed to poultry in 1997 and again in 2003. The most authoritative [review](#) on 'Novel influenza A viruses and pandemic threats' is still by Timothy Uyeki, Jacqueline Katz and Daniel Jernigan from the American CDC.

In this review, we include an article estimating how long a childhood influenza vaccination may last ([Lancet Respir Med](#)), articles to assess the global burden of the seasonal influenza ([Lancet Respir Med](#)) and the clinical efficacy of a new antiviral medication ([N Engl J Med](#)), and evidence that we may have to add aspergillus pneumonia to the complications of an influenza infection ([Lancet Respir Med](#)). A great proof-of-concept [study](#) from our colleagues in Wellington, using high-flow, high-temperature, humidified air to reduce the symptoms related to the common cold, receives our 'butterfly' in this selection.

Globally, 291.8 million people per year suffer from LRTIs (lower respiratory tract infections), resulting in more than 2.7 million deaths. One of the common causes of this in adults and children is streptococcal pneumonia, with the mortality hardly changed since the introduction of antibiotics in the 1950s. In *Respiratory Research Review* [issue 147](#), we reviewed evidence of nonrespiratory death following pneumonia, such as increased rates of cardiac events. In this issue, we [review](#) the 1-year mortality following an empyema, which again is surprisingly high, at up to 45%. Colleagues in Milan call 'pneumonia a neglected problem' and cite that on ClinicalTrials.gov, only 154 studies are listed involving bacterial pneumonia, versus more than 7000 studies involving HIV [infection](#). One of these [studies](#) involving pneumonia is 'Omadacycline for community-acquired bacterial pneumonia', which we will review in this issue.

At this stage, penicillin and β-lactam antibiotics are still the antibiotics of choice for streptococcal infections in NZ. We want to draw attention to the *JAMA* [review](#) and associated video on the 'evaluation and management of penicillin allergy'. In the US, about 10% of the population report an adverse reaction to penicillin; however, 95% of people can tolerate penicillin. The authors give practical hints on how to retake a drug history, when to consider a drug challenge and when to consider skin testing. Their solutions are safe, pragmatic and easy enough to adopt in clinical practice.

We hope you enjoy this selection, and we are looking forward to your feedback, comments and suggestions.

Kind regards

Professor Lutz Beckert

[lutzbeckert@researchreview.co.nz](mailto:lutzbeckert@researchreview.co.nz)

### KINDLY SUPPORTED BY



# SPIRIVA®

(tiotropium)



## Now FULLY FUNDED with NO Special Authority\*

\*Pharmaceutical Schedule, [www.pharmac.govt.nz](http://www.pharmac.govt.nz). Prescription must be endorsed that the patient has been diagnosed as having COPD using spirometry **PRESCRIPTION MEDICINE**. Spiriva® Capsules and Spiriva® Respimat® are indicated for long term, once-daily maintenance treatment in patients with COPD (including chronic bronchitis and emphysema), to reduce airflow obstruction, to improve quality of life and to reduce associated dyspnoea. Before prescribing please review the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects on the Medsafe website: [www.medsafe.govt.nz](http://www.medsafe.govt.nz) Boehringer Ingelheim (NZ) Ltd, Auckland NZ/SPI-181090a TAPS PP2988

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017

Authors: GBD 2017 Influenza Collaborators

**Summary:** Using data from the Global Burden of Disease Study 2017, LRTI incidences, hospitalisations and mortality attributable to influenza were modelled for every country and selected regions for 1990–2017. Across all ages, influenza LRTIs were responsible for an estimated 145,000 deaths in 2017, with the highest rates for adults aged >70 years (16.4 deaths per 100,000) and for eastern Europeans (5.2 per 100,000). An estimated 9,459,000 hospitalisations covering 81,536,000 hospital days could be attributed to LRTIs. It was also estimated that 11.5% of LRTI episodes were attributable to influenza, corresponding to 54,481,000 episodes, including 8,172,000 severe episodes.

**Comment:** About 150,000 deaths secondary to LRTIs or about 5% of all deaths due to LRTIs are secondary to influenza, according to the Global Burden of Disease influenza collaborators. People above the age of 70 years have the highest infection rate and the highest mortality. However, Sheena Sullivan and Benjamin Cowling from the WHO Collaborating Centre for Reference and Research on Influenza argue in their accompanying [editorial](#) that this number is far too low, because of methodological weaknesses and by restricting the death due to LRTIs. **Bottom line: influenza has a considerable death toll even outside pandemics.**

Reference: *Lancet Respir Med* 2019;7:69–89

[Abstract](#)

[CLICK HERE](#) to read previous issues of Respiratory Research Review

### Independent commentary by Professor Lutz Beckert.

Professor Lutz Beckert is the Head of Department of Medicine of the University of Otago, Christchurch. He is also a Respiratory Physician at Canterbury District Health Board.

FOR FULL BIO [CLICK HERE](#)



**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.

## Baloxavir marboxil for uncomplicated influenza in adults and adolescents

Authors: Hayden FG et al., for the Baloxavir Marboxil Investigators Group

**Summary:** Outpatients aged 12–64 years with acute uncomplicated influenza received baloxavir marboxil 10–40mg in a dose-ranging, placebo-controlled trial, after which 1064 (84.8–88.1% with influenza A [H3N2] infection) were randomised to receive baloxavir 40mg or 80mg according to bodyweight, oseltamivir 75mg twice daily or placebo during the 2016–2017 influenza season. In the phase 2 trial, alleviation of influenza symptoms was seen a median of 23.4–28.2 hours faster with baloxavir than with placebo ( $p < 0.05$ ). In the phase 3 trial, baloxavir recipients had a quicker time to alleviation of symptoms than placebo recipients (53.7 vs. 80.2 hours [ $p < 0.001$ ]) with a similar time to symptom alleviation as oseltamivir recipients. Baloxavir recipients also experienced greater reductions in viral load the day after starting treatment compared with placebo and oseltamivir recipients. The respective adverse event rates in the baloxavir, oseltamivir and placebo arms were 20.7%, 24.8% and 24.6%.

**Comment:** In October 2018, the US FDA-approved a new class of antiviral agent, baloxavir, which is given as a single dose and inhibits the endonuclease within the viral polymerase acid protein subunit. In this international trial, the investigators randomised around 1400 participants with influenza symptoms within 48 hours to baloxavir, oseltamivir or placebo. Baloxavir was well tolerated and led to earlier resolution of symptoms and earlier viral load clearance when compared with placebo. **Bottom line: baloxavir is a step forward in antiviral therapy and has the potential to be combined with oseltamivir.**

Reference: *N Engl J Med* 2018;379:913–23

[Abstract](#)

COMPARING DUAL BRONCHODILATORS FOR COPD?

Prescribe Anoro instead of Spiolto\* for superior improvement in lung function\*\*<sup>1</sup>

**ANORO ELLIPTA**  
umeclidinium/vilanterol

\*Spiolto is a trademark of Boehringer Ingelheim \*\*Trough FEV<sub>1</sub> improved from baseline by 180mL for ANORO Ellipta (n=225) vs. 128mL for Spiolto (n=224) at week 8, in the ITT population; difference 52mL (95% CI: 28, 77;  $p < 0.001$ ) **References:** 1. Feldman GJ et al. *Adv Ther* 2017; 34:2518–2533 **Anoro® Ellipta®** (umeclidinium bromide/vilanterol trifenate inhaler 62.5/25mcg per inhalation) is a **Prescription Medicine**. *Anoro Ellipta* is indicated as a long-term maintenance bronchodilator treatment to relieve symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). **Anoro Ellipta is a fully funded medicine; Special Authority criteria apply. Maximum Daily Dose:** One inhalation once daily. **Contraindications:** Patients with severe milk-protein allergy or those who have hypersensitivity to umeclidinium, vilanterol or any excipients. **Side Effects:** Nasopharyngitis, oropharyngeal pain, sinusitis, pharyngitis, cough, urinary tract infection, constipation, dry mouth, hypertension, upper respiratory tract infections. **Warnings and Precautions:** Not recommended for use in patients with asthma or for relief of acute symptoms or an acute exacerbation. Use care when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole), beta-blockers and in patients with severe cardiovascular disease, narrow-angle glaucoma or urinary retention. Before prescribing *Anoro Ellipta*, please review the Data Sheet at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). *Anoro* and *Ellipta* are registered trade marks of the GlaxoSmithKline group of companies. Anoro Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. **Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS DA1924JB-PM-NZ-UCV-ADVT-190010**

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## Effectiveness of influenza vaccination on influenza-associated hospitalisations over time among children in Hong Kong

Authors: Feng S et al.

**Summary:** Influenza vaccine effectiveness was investigated in children admitted to hospital for respiratory infections during 2012–2017, comparing those who tested positive for influenza A or B (cases; n=2500) with those who tested negative (n=13,195; controls). For the influenza-positive and -negative groups, the respective vaccination rates were 6.4% and 11.0%. Influenza-related admissions peaked in January–March over 2012–2017 with a large summer peak in 2016. The respective pooled vaccine effectiveness rates were 79%, 67% and 43% for September–December, January–April and May–August, with estimated rates of 79%, 60%, 57% and 45% within 0.5–2, 2–4, 4–6 and 6–9 months of vaccination, respectively. Analyses by type and subtype showed that vaccine effectiveness rates fell by 2–5 percentage points each month.

**Comment:** NZ is just running through its cycle of influenza vaccinations, targeting in particular children aged 6 months to 3 years, adults above the age of 65 years and special groups ([Influenza: Immunisation Handbook 2017](#); pdf, 784KB). Hong-Kong offers vaccinations for children aged 6 months to 12 years. These Chinese/Australian researchers report on the protection conferred by the seasonal influenza vaccination. The efficacy varied a little from year to year, and the effectiveness against influenza A (H3N2) appears to be the lowest. **Bottom line: a protective effect was available within 2 weeks; however, this effect was less than 50% after 6 months. Currently, annual vaccination is the most effective strategy to protect from influenza.**

Reference: *Lancet Respir Med* 2018;6:925–34

[Abstract](#)

## Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza

Authors: Schauwvlieghe AFAD et al., on behalf of the Dutch-Belgian Mycosis study group

**Summary:** The incidence of invasive pulmonary aspergillosis was investigated over several influenza seasons for a retrospective cohort of 432 adults admitted to an ICU with influenza, with assessment of whether influenza was an independent risk factor for those who were diagnosed with invasive pulmonary aspergillosis a median of 3 days after ICU admission (n=83). Compared with nonimmunocompromised patients (n=315), those who were immunocompromised (n=117) had a higher incidence of invasive pulmonary aspergillosis (32% vs. 14%). Compared with patients who did not develop invasive pulmonary aspergillosis, those who did had a higher 90-day mortality rate (51% vs. 28% [p=0.0001]). Influenza was found to be a significant independent predictor for invasive pulmonary aspergillosis (adjusted odds ratio 5.19 [95% CI 2.63, 10.26]), as were higher APACHE II score, male sex and corticosteroid use.

**Comment:** It has been suspected that the primary cause of death during the influenza pandemic was a secondary bacterial infection. This is a fascinating study from the Dutch-Belgian Mycosis study group, who systematically investigated 432 patients admitted to ICUs with severe influenza. An influenza superinfection occurred in almost 20% of the patients, and once infected, the mortality in this group was 45%. Prior treatment with corticosteroids increased the risk of invasive aspergillosis by about 50%. The accompanying [editorial](#) gives us the **bottom line: we need to add invasive pulmonary aspergillosis to the list of influenza complications.**

Reference: *Lancet Respir Med* 2018;6:782–92

[Abstract](#)

## Randomised controlled trial of rhinotherapy for treatment of the common cold

Authors: van de Hei S et al.

**Summary:** Adult participants presenting within 48 hours of developing symptoms of a common cold were randomised 2:1 to receive rhinotherapy with 35 L/min of 100% humidified air at 41°C via high-flow nasal cannulae, 2 hours per day for ≤5 days, or vitamin C (ascorbic acid) 250 mg/day for 5 days as a control in this feasibility trial from NZ. Thirty of 79 potential participants (38%) screened for eligibility were randomised (primary outcome), all of whom completed the study. Compared with vitamin C, rhinotherapy was associated with greater reductions from baseline in modified Jackson score at days 2–6, with the maximum difference of –6.4 points seen at day 4; a 5-point change was designated the threshold for substantial clinical benefit.

**Comment:** In this proof of concept study, our colleagues in Wellington used hot (41°C), humidified air at 35 L/min to treat the common cold. Adults contract about 2–4 ‘colds’ per year, with an estimated loss of productivity of US\$40 billion a year in the US alone. In this feasibility study, our colleagues randomised patients to rhinotherapy at 41°C for 2 hours versus low-dose vitamin C. Rhinotherapy was well tolerated without mucosa burns. Although not a primary endpoint, the modified Jackson score showed considerable improvement in the rhinotherapy group. **Bottom line: it is feasible to perform an RCT to explore rhinotherapy for the common cold.**

Reference: *BMJ Open* 2018;8:e019350

[Abstract](#)

## Omadacycline for community-acquired bacterial pneumonia

Authors: Stets R et al.

**Summary:** Intent-to-treat data were reported for adults with CAP who were treated with intravenous omadacycline 100mg every 12 hours for two doses then 100mg every 24 hours (n=386) or intravenous moxifloxacin 400mg every 24 hours (n=388). Participants could transition to oral omadacycline 300mg every 24 hours or moxifloxacin 400mg every 24 hours after 3 days; the total treatment duration was 7–14 days. Omadacycline was noninferior to moxifloxacin for the primary endpoint of early clinical response (survival with improvements in ≥2 of cough, sputum production, pleuritic chest pain and dyspnoea, and no worsening of symptoms at 76–120 hours, without any rescue antibacterial therapy), with rates of 81.1% and 82.7%, respectively; the corresponding rates of investigator-assessed clinical response at 5–10 days after the last dose were 87.6% and 85.1%. After commencing treatment, adverse events were reported by 41.1% of the omadacycline arm and 48.5% of the moxifloxacin arm; the most commonly reported events were gastrointestinal (10.2% and 18.0%, respectively), with diarrhoea affecting fewer omadacycline recipients than moxifloxacin recipients (1.0% vs. 8.0%).

**Comment:** This RCT introduces a new antibiotic, derived from the tetracycline class, that overcomes the mechanism of tetracycline resistance. The research team, with the first three authors from Zaporizhzhia, Bucharest and Manila, co-ordinated 86 centres in Europa, North America, South America, Middle East, Africa and Asia to randomise patients with severe CAP to moxifloxacin or omadacycline. Overall, omadacycline was well tolerated with only minor side effects. **Bottom line: once-daily omadacycline was noninferior to moxifloxacin for the treatment of adults hospitalised for CAP.**

Reference: *N Engl J Med* 2019;380:517–27

[Abstract](#)



NZMA  
South GP CME  
General Practice Conference & Medical Exhibition  
08-11 AUGUST 2019  
HORNCASTLE ARENA  
CHRISTCHURCH  
gpcme.co.nz



NZMA  
Rotorua GP CME  
General Practice Conference & Medical Exhibition  
20-23 JUNE 2019  
ENERGY EVENTS CENTRE  
ROTORUA  
gpcme.co.nz

## Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: impact of $\beta$ -lactam plus macrolide combination therapy

**Authors:** Okumura J et al., on behalf of the Central Japan Lung Study Group

**Summary:** This *post hoc* analysis of data from a prospective cohort of patients with CAP (community-acquired pneumonia) at low risk of a drug-resistant pathogen evaluated 30-day differences in mortality between those treated with non-antipseudomonal  $\beta$ -lactam monotherapy (n=369) and those who additionally received a macrolide (n=225). Compared with monotherapy recipients, those who received a non-antipseudomonal  $\beta$ -lactam plus a macrolide had a significantly lower 30-day mortality rate (1.8% vs. 13.8%; adjusted odds ratio 0.28 [95% CI 0.09, 0.87]). Factors significantly, independently associated with 30-day mortality included PaCO<sub>2</sub> >50mm Hg, leucocyte count <4000 cells/mm<sup>3</sup>, nonambulatory status, albumin level <3.0 g/dL, haematocrit <30%, age  $\geq$ 80 years, respiratory rate >25 breaths per minute and body temperature <36°C.

**Comment:** A group of Japanese researchers from Nagoya retrospectively reviewed the 30-day mortality of around 600 patients with CAP. Around 350 were treated with a  $\beta$ -lactam antibiotic alone, and around 250 were treated with a combination of  $\beta$ -lactam/macrolide antibiotics. The mortality rate in the first group was 18%, compared with less than 2% in the combination group. Grant Waterer wrote the [editorial](#), reviewing other evidence for early treatment and combination therapy with a macrolide. In case he would ever be admitted with CAP, his **bottom line is: "a macrolide followed a short time later by a third generation cephalosporin please, preferably getting both within 2 h of presenting"**.

**Reference:** *Respirology* 2018;23:526–34

[Abstract](#)

## Bacteriology and clinical outcomes of patients with culture-positive pleural infection in Western Australia

**Authors:** Brims F et al.

**Summary:** These authors presented a 6-year analysis of the bacteriology and clinical outcomes of 601 Western Australian adults with CCPI (culture-positive pleural infection); 894 bacterial isolates were identified. Hospital- and community-acquired CPPI was documented for 66.2% and 27.3% of the patients, respectively, with the remainder classified as oesophageal rupture/leak. The proportion of patients with comorbidities was 65.2%, mostly cancer. There was radiological evidence of pneumonia in 43.8% and 27.3% of patients with community- and hospital-acquired CPPI, respectively. *Streptococcus* spp. (32.9%), particularly viridans streptococci group, were the most frequently occurring of the 153 bacterial strains cultured among patients with community-acquired CPPI, whereas *Staphylococcus aureus* (11.6%) and Gram-negative (31.9%) infections were the most frequent among patients with hospital-acquired CPPI. The respective in-hospital mortality rates were similar for patients with community- versus hospital-acquired CCPI (13.4% vs. 16.6% [p=0.417]), but a significant difference was seen for 1-year mortality (32.4% vs. 45.5% [p=0.006]).

**Comment:** Our colleagues from Perth followed more than 600 cases of patients with culture-positive empyema. Given that about half of the 4 million patients with pneumonia develop an effusion, it is surprising how little we know about empyema. The Perth group found evidence of pneumonia in only about 40% of the community-acquired culture-positive effusions and in less than 30% of hospital-acquired ones. Pyng Lee provides context in the accompanying [editorial](#), as well as linking back to Hippocrates. **Bottom line: patients with a community-acquired infection have a more than 30% and patients with a hospital-acquired pleural infection have a 45% 1-year mortality.**

**Reference:** *Respirology* 2019;24:171–8

[Abstract](#)



Time spent reading this publication has been approved for CME for Royal New Zealand College of General Practitioners (RNZCGP) General Practice Educational Programme Stage 2 (GPEP2) and the Maintenance of Professional Standards (MOPS) purposes, provided that a Learning Reflection Form is completed. Please [CLICK HERE](#) to download your CPD MOPS Learning Reflection Form. One form per review read would be required.



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

## A pilot feasibility study in establishing the role of ultrasound-guided pleural biopsies in pleural infection

**Authors:** Psallidas I et al.

**Summary:** The AUDIO study recruited 20 patients with pleural infection to evaluate the feasibility of using ultrasound-guided pleural biopsy culture to increase microbiological yield. Exploratory analyses used the 16S ribosomal RNA technique to assess its utility for increasing microbiological diagnosis speed and accuracy. There were no adverse events associated with ultrasound-guided pleural biopsy, which increased microbiological yield compared with pleural fluid and blood culture samples (45% vs. 20% and 10%, respectively). The 16S ribosomal RNA technique was successfully applied to pleural biopsy samples, with sensitivity and specificity values of 93% and 89.5%, respectively.

**Comment:** This is an intriguing proof-of-concept study exploring pleural infections, which, according to the authors, occur in the US and UK in 80,000 people per year, with 220 new cases per day. Making a microbiological diagnosis using standard techniques is often surprisingly difficult. These researchers used ultrasound guidance to avoid the intercostal arteries, the biopsy 'guns' used for lung fine needle aspirates, and DNA extraction tuning into the bacterial ribosomal DNA. **Bottom line: pleural biopsies were safe in patients with pleural infections and increased the microbiological yield to confirm a diagnosis.**

**Reference:** *Chest* 2018;154:766–72

[Abstract](#)

## Predictive variables for failure in administration of intrapleural tissue plasminogen activator/deoxyribonuclease in patients with complicated parapneumonic effusions/empyema

**Authors:** Khemasuwan D et al.

**Summary:** This retrospective analysis included the medical charts of 84 patients receiving chest tube drainage and combined intrapleural therapy with tPA (tissue plasminogen activator) and DNase (deoxyribonuclease) for complicated pleural effusion/empyema. The study researchers sought to determine which clinical and radiological features indicate failure of combined intrapleural therapy. Two-thirds of the patients achieved resolution of complicated pleural effusion/empyema with intrapleural tPA/DNase. The researchers coupled an ensemble machine learning method with decision trees and hyperparameter tuning to mitigate overfitting to rank the importance of 19 candidate clinical variables with respect to their ability to predict failure of tPA/DNase therapy. Of all candidate predictors, the presence of pleural thickening was the most important (48% relative importance), followed by the presence of an abscess or necrotising pneumonia (24%), the pleural protein level (6%) and the presence of loculated effusion (4%).

**Comment:** In this retrospective study of 84 patients, the North American authors explored factors reducing the success rate of tPA/DNase in patients with a complicated pleural effusion or empyema. Their overall success rate seemed low at 68% and 27 patients required surgical intervention. The authors don't comment on the timing of installing fibrinolytic therapy and are tough on their expectation of (near) complete resolution. They used a machine learning algorithm and identified features suggesting a low success rate of fibrinolysis ([Chest](#)). **Bottom line: pleural thickening, lung abscess and necrotising pneumonia are risk factors for failure of fibrinolytic therapy.**

**Reference:** *Chest* 2018;154:550–6

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

**RACP MyCPD Program participants** can claim **one credit per hour** (maximum of 50 credits per year) for reading and evaluating Research Reviews.

**FOR MORE INFORMATION CLICK HERE**